New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
13:25 EDTJAZZ, JAZZ, JAZZ, SLXP, SLXP, SLXPLeerink's specialty pharma analyst holds analyst/industry conference call
Specialty Pharmaceuticals Analyst Gerberry discusses the prospects for Jazz Pharmaceuticals/Sigma Tau's Defibrotide approval in the U.S., and provides an assessment of challneges facing two key specialty pharma controversies: Defibrotide and Relistor on an Analyst/Industry conference call to be held on February 27 at 2 pm.
News For JAZZ;SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 1, 2016
09:08 EDTJAZZJazz Pharmaceuticals reports data from Phase 3 pivotal study of defibrotide
Jazz Pharmaceuticals announced that data from the phase 3 pivotal study of defibrotide were published online in BLOOD, the Journal of the American Society of Hematology, or ASH. The data demonstrated that defibrotide use in patients with hepatic veno-occlusive, or VOD, also known as sinusoidal obstruction syndrome, with multi-organ failure post-hematopoietic stem-cell transplantation was associated with a statistically significant improvement in Day +100 survival and in rate of complete response by Day +100, compared with rigorously selected historical controls.
January 29, 2016
06:55 EDTJAZZ2016 could be pivotal year for Jazz, says Deutsche Bank
Deutsche Bank analyst Gregg Gilbert says 2016 could be a pivotal year for Jazz Pharmaceuticals. The analyst sees several potential catalysts for the shares, including potentially greater certainty on Xyrem duration via a patent settlement or a win in court, FDA approval of defibrotide and acquisitions supported by the company's under-leveraged balance sheet. Gilbert keeps a Buy rating on Jazz with a $167 price target.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use